2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Biological Processes, Apoptosis, Metabolism, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Study Population, Human, Adult, Elderly
PAPER

5148 MM1YA-A04 (Alliance), a phase II myelomatch subprotocol comparing cytarabine/daunorubicin + gemtuzumab ozogamicin (GO) versus cytarabine/daunorubicin + venetoclax for newly diagnosed core binding factor acute myeloid leukemia (CBF-AML) in younger adults

Ramzi Abboud, MD, Jun Yin, PhD2, Yehuda Deutsch, MD3, Marina Konopleva, MD, PhD4, Antoine N. Saliba, M.D.5, Emily Curran, MD6, Eric Stephen Winer, MD7, Richard F. Little, MD8, Richard Stone, MD9, Selina Luger, MD, FRCPC10, Ehab Atallah, MD11, Brent Wood, MD, PhD12, Jerald Radich, MD13, Cecilia CS Yeung, MD, Professor Pathology14, Shahanawaz Jiwani, MBBS, PhD15, Harry Erba, MD, PhD16, Mark R. Litzow, MD17, Wendy Stock, MD18, Celalettin Ustun, MD19, Geoffrey L. Uy, MD20
1 Washington University in Saint Louis, Saint Louis, Missouri, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Memorial Healthcare Systems, Palm Coast, Florida, United States
4 Albert Einstein Memorial, Washington, District of Columbia, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 University of Cincinnati, Cincinnati, Ohio, United States
7 Dana Farber Cancer Institute, Boston, Massachusetts, United States
8 NIH, Bethesda, Maryland, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
12 Keck School of Medicine of USC - Department of Surgery, Los Angeles, California, United States
13 Fred Hutch Cancer Center, Seattle, Washington, United States
14 Fred Hutch Cancer Center, Seattle, Washington, United States
15 Pilot Plant- Frederick National Lab, Frederick, Maryland, United States
16 Duke Apheresis Center-Clinic 2N, Durham, North Carolina, United States
17 Mayo Clinic Rochester mn, Foley, Alabama, United States
18 University of Chicago, Chicago, Illinois, United States
19 Rush University College of Health Sciences, Chicago, Illinois, United States
20 Washington University in Saint Louis, Saint Louis, Missouri, United States

Authors: Ramzi Abboud, Jun Yin, Yehuda Deutsch, Marina Konopleva, Antoine Saliba, Emily Curran, Eric Winer, Richard Little, Richard Stone, Selina Luger, Ehab Atallah, Brent Wood, Jerry Radich, Cecelia Yeung, Shahanawaz Jiwani, Harry Erba, Mark Litzow, Wendy Stock, Celalettin Ustun Geoffrey Uy

Background/Rationale: Although CBF-AML is biologically favorable subset of AML, relapse and regimen-related toxicity remain major barriers. The addition of GO to intensive chemotherapy in CBF-AML improves survival but is associated with added toxicity including thrombocytopenia and veno-occlusive disease. KIT mutations are associated with poor prognosis in CBF-AML.  RAS mutations are common in CBF-AML, but their impact on outcomes is not well-established. The BCL2 inhibitor venetoclax is established in the treatment of AML with hypomethylating agents, and venetoclax has shown feasibility with intensive AML induction regimens.    We hypothesize that replacing GO with venetoclax – in combination with intensive chemotherapy -  will result in higher rates of complete remission without measurable residual disease (CRMRD-), reduced toxicity, and improved outcomes in patients with CBF-AML.

Study Design: MyeloMATCH (Myeloid Malignancies Molecular Analysis for Therapy Choice) is a National Cancer Institute–led precision medicine platform trial that uses rapid genomic profiling to match patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to biomarker-driven clinical trials evaluating targeted therapies across multiple treatment stages within a single adaptive trial framework.  MM1YA-A04 (NCT06917911), a myeloMATCH subprotocol, is a randomized, open-label, multicenter phase II trial. Eligible patients are first assigned through the myeloMATCH Master Screening and Reassessment Protocol, then registered to MM1YA-A04. Patients will be registered in to two separate cohorts: cohort 1:  RAS or KIT-mutated, cohort 2 RAS and KIT-nonmutated. In each cohort, patients will be randomized at 1:1 ratio to 7+3+GO vs. 7+3+venetoclax and the cohorts will be analyzed separately. Patients will be stratified by RUNX1::RUNX1T1 and CBFB::MYH11 fusions. 

Key Eligibility Criteria: Age 18–59 years; newly diagnosed CBF-AML with t(8;21)/RUNX1::RUNX1T1 or inv(16)/t(16;16)/CBFB::MYH11; protocol-defined adequate major organ function; no FLT3 mutation; ECOG ≤3; no prior AML/MDS-directed therapy except urgent cytoreduction.

Treatment: Enrolled patients receive induction with cytarabine 100 mg/m²/day continuous IV days 1–7, daunorubicin 60 mg/m²/day IV days 1–3, and either GO 3 mg/m² (max 4.5 mg) IV days 1 and 4 or venetoclax ramp-up: 50 mg day 1, 100 mg day 2, 200 mg day 3, then 400 mg daily days 4–11.

Primary Endpoint: CRMRD- by end-of-one induction bone marrow assessment, using multiparameter flow cytometry with MRD threshold <10⁻³. The primary analysis is intent-to-treat.

Secondary and Exploratory endpoints: Include CR, composite CR/CRi/CRh, overall survival (OS), event free survival (EFS), cumulative incidence of relapse, cumulative incidence of death, 30- and 60-day early death, adverse events, RAS/KIT as predictive biomarkers, comparison of flow MRD with fusion-transcript/NGS-based MRD, and correlative evaluation of KIT VAF/exon location, CD33 expression, secondary mutations, cytogenetics, and RUNX1::RUNX1T1 versus CBFB::MYH11 subsets.

Statistical Plan: The total planned accrual is 162 patients: 92 in the RAS/KIT-mutated cohort and 70 in the RAS/KIT-nonmutated. Each cohort will be analyzed separately and has a 50% non-binding futility interim analysis.  Final comparisons use two-proportion z-tests for CRMRD- superiority of the experimental arm.

Current Status: The MM1YA-A04 trial is conducted through the National Clinical Trials Network in the United States and opened in May 2026.

Support: U10CA180821, U10CA180882;
https://acknowledgments.alliancefound.org

Ramzi Abboud, MD: No relevant conflicts of interest to declare.